SUBSCRIBE
SUBSCRIBE

George Budwell

Courtesy of inside-studio/Getty Images
Business
Ipsen to Acquire Albireo for Rare Disease Portfolio
Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.
January 9, 2023
 · 
1 min read
 · 
George Budwell
Courtesy Niels Wenstedt/BSR Agency via Getty Image
Business
Fate Ends Potential $3B Janssen Partnership
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
January 6, 2023
 · 
1 min read
 · 
George Budwell
Senior lady massaging hand suffering from rheumatoid arthritis concept, old adult female patient touching wrist feeling hurt joint pain having osteoarthritis disease health problem, close up view
Policy
Aurinia and Sun Pharma File Joint Motion to Settle Patent Dispute
Aurinia and Sun Pharma agree to file a joint motion to dismiss a key patent dispute.
January 3, 2023
 · 
2 min read
 · 
George Budwell
CIDEB gene can be the game changer in NASH
Drug Development
Madrigal Pharmaceuticals Breaks Through In NASH With Late-Stage Win
Madrigal’s NASH drug hits the mark in late-stage trial.
December 19, 2022
 · 
2 min read
 · 
George Budwell
Courtesy of Enlaza Therapeutics
Business
Synthetic Biology Welcomes Enlaza Therapeutics to the Game
Covalent biologic company Enlaza launches with $61M in seed financing.
December 16, 2022
 · 
2 min read
 · 
George Budwell
Business
Biopharma’s 5 Biggest M&A Deals of 2022
See inside for BioSpace’s compilation of the five biggest M&A deals of 2022.
December 14, 2022
 · 
3 min read
 · 
George Budwell
Courtesy of Getty Images
Drug Development
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
Wall Street is no longer enamored with NASH drug developers.
December 11, 2022
 · 
5 min read
 · 
George Budwell
NRX-101
Drug Development
Psychedelic Medicine Takes Another Step Forward with Compass’ Twin Updates
Compass’ twin clinical updates regarding its lead candidate spotlight the promise of psychedelic medicine.
December 8, 2022
 · 
2 min read
 · 
George Budwell
David L. Ryan/The Boston Globe via Getty
Business
Vertex Pursues Myotonic Dystrophy with $250M Entrada Deal
Vertex Pharmaceuticals agreed to a collaboration deal with Entrada Therapeutics. The two companies announced a collaboration to develop an intracellular Endosomal Escape Vehicle.
December 8, 2022
 · 
1 min read
 · 
George Budwell